A Phase 3 interventional study of oxycodone HCl and naltrexone HCl extended-release capsules in Chronic Noncancer Pain, sponsored by Pfizer. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-21.
Sponsored by Pfizer · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.
Among the 50 studies testing oxycodone in Pain, this one is the 4th largest by enrollment, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 12th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:
Kafrelsheikh University · Sites in Egypt
Ages 18–65
University of Florida · Sites in United States
Ages 45–85 · Healthy volunteers
University of Florida · Sites in United States
Ages 21–45 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 395 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 67 across the 50 interventional studies. Of the 37 that completed or were terminated, 13 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 50 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 18th largest by enrollment of the 71 interventional ones that give a count, is one of 10 that started in 2010, is one of 28 in phase 3, and was the 52nd registered.
Pfizer’s Pain studies by the year they started, since 2001.
3 of the studies testing oxycodone in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05761860University of FloridaThe Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults | 2026-12 |
| NCT04218409University of FloridaOpioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination | 2026-12-31 |
| NCT05548582Johns Hopkins UniversityReduced Opioid Prescription After Laparoscopic Hysterectomy | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies testing oxycodone in Pain, from their registry updates:
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules in a chronic noncancer pain population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: oxycodone HCl and naltrexone HCl extended-release capsules
Drug pages: Oxycodone · Naltrexone
Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
Also known as: ALO-02
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE that was attributed to study drug in a participant who received study drug was defined as an adverse reaction. Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to end of study (2 weeks post-end of month 12)
Number of Participants With Treatment Emergent (TE) Adverse Events (AEs) Based on Intensity
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of adverse event was defined on the basis of severity of an event and was classified as; mild (does not interfere with participant's usual function), moderate (interferes to some extent with participant's usual function) and severe (interferes significantly with participant's usual function). Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to end of study (2 weeks post-end of month 12)
Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score
The presence and level of clinical opiate withdrawal signs or symptoms was determined by clinician-administered, clinical opiate withdrawal scale (COWS). It contains 11 common opiate withdrawal signs or symptoms rated by clinician (resting pulse rate, gastrointestinal upset, sweating, tremor, restlessness, yawning, pupil size, anxiety or irritability, bone or joint aches, gooseflesh skin, runny nose or tearing), rated on either 3-point, 4-point or 5-point scale, higher score indicated more symptoms of withdrawal. The total score is the sum of all items, ranging from 0 to 48, higher score indicated severe withdrawal. Participants were categorized as less than mild (score 0-4) mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36). Percentage of participants with mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36) were reported.
Time frame: Baseline up to Month 12
Subjective Opiate Withdrawal Scale (SOWS) Score
The presence and level of clinical opiate withdrawal signs or symptoms was determined by participant-reported instrument, subjective opiate withdrawal scale (SOWS). It contains 16 symptoms of opiate withdrawal rated by the participant (anxiety, yawning, sweating, tearing, running nose, goose bumps, shaking, hot flashes, cold flashes, bone or muscle aches, restlessness, nauseous, vomiting, muscle twitch, stomach cramps and feel like using now). Each item is rated on a 5-point scale (0= not at all, 1= a little, 2= moderate, 3= quite a bit, 4= extreme). The total score is the sum of all items, ranging from 0 to 64, higher score indicated severe withdrawal.
Time frame: Baseline, Week 1, 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Observed Steady-state Plasma Concentrations (Cobs) of Oxycodone
Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination
Observed Steady-state Plasma Concentrations (Cobs) of Noroxycodone
Noroxycodone was a metabolite of Oxycodone.
Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination
Observed Steady-state Plasma Concentrations (Cobs) of Naltrexone
Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination
Observed Steady-state Plasma Concentrations (Cobs) of 6-Beta-naltrexol
6-Beta-naltrexol was a metabolite of naltrexone.
Time frame: Week 1, 4, Month 2, 3, 6, 9, 12 or early termination
Time to Stabilization of Study Medication
Stabilization was considered to have occurred when: total daily dose of oxycodone and naltrexone remained unchanged for greater than or equal to (\>=) 3 consecutive days, daily acetaminophen used remained at 1 gram or less and immediate-release oxycodone was not being used as a rescue medication. Days to stabilization = date of stabilization - date of first dose + 1.
Time frame: Baseline up to Month 12
Duration of Exposure to Study Medication
Duration of exposure to study medication during the course of the study was assessed.
Time frame: Baseline up to 2 weeks after last dose
Mean Daily Dose of Study Medication (Oxycodone Component)
Time frame: Baseline- less than (<) Week 1, Week 1-<4, Week 4-<Month 2, Month 2-<3, Month 3-<4, Month 4-< 5, Month 5-<6, Month 6-<7, Month 7-<8, Month8-<9, Month 9-<10, Month 10-<11, Month 11-<12, Month 12-<End of study (2 weeks post end of Month 12)
Number of Participants With Rescue Medication (Acetaminophen Tablets)
Participants had acetaminophen up to 2 grams per day during the treatment period of the study as rescue medication.
Time frame: Baseline- less than (<) Week 1, Week 1-<4, Week 4-<Month 2, Month 2-<3, Month 3-<4, Month 4-< 5, Month 5-<6, Month 6-<7, Month 7-<8, Month8-<9, Month 9-<10, Month 10-<11, Month 11-<12, Month 12-<End of study (2 weeks post end of Month 12)
Percentage of Participants With Response to Urine Drug Test
Participants with a positive urine drug test for illicit drug substances (marijuana, cocaine, amphetamines, methamphetamines, phencyclidine, and ecstasy), or unexpected drug substances (those other than reported by the participant as therapeutic concomitant medications such as opiates and methadone), or a negative urine test for the expected opioid (oxycodone) was assessed.
Time frame: Screening, Week 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or early termination
Percentage of Participants With Current Opioid Misuse Measure (COMM) Score of 9 or Above
The COMM is a 17-item self-report questionnaire to monitor for aberrant medication-related behaviors among chronic pain participants. Participants are asked to indicate the frequency of individual behaviors on a scale from 0 to 4 (0 = never, 1 = seldom, 2 = sometimes, 3 = often, 4= very often). The total COMM score is the sum of the 17 item scores with a range from 0 to 68. Higher score indicated a higher risk for aberrant medication- related behavior. A score of 9 or higher was defined as high risk for aberrant medication- related behavior.
Time frame: Baseline, Week 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or early termination
Mean Daily Dose of Immediate-release Oxycodone as Rescue Medication
Immediate-release oxycodone as a single ingredient product was used as a rescue medication only during the first 4 weeks of the treatment period to support the initiation of oxycodone HCl and naltrexone HCl treatment.
Time frame: Up to Week 4
Participants Global Assessment of Treatment Satisfaction
Participant global assessment of treatment satisfaction was scored on a 5-point categorical scale based on response to the question "Please rate your overall satisfaction with the study drug you received?" where 1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = very satisfied.
Time frame: Week 1, 4, Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, end of treatment
Mean Change From Baseline in Pain Right Now Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain right now" was reported.
Time frame: Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination (ET)
Mean Change From Baseline in Average Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. Pain on average in the last 24 hours" was reported.
Time frame: Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
Mean Change From Baseline in Worst Pain Score at Weeks 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain at its worst in the last 24 hours" was reported.
Time frame: Baseline, Week 1, 4, Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 12 or Early Termination
| Milestone | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Started | 395 |
| Completed | 158 |
| Not completed | 237 |
| Withdrew: Adverse event | 75 |
| Withdrew: Withdrawal by subject | 51 |
| Withdrew: Lack of efficacy | 37 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Death | 1 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Physician decision | 12 |
| Withdrew: Non-compliant | 25 |
| Withdrew: Confirmed positive urine drug test | 8 |
| Withdrew: Sponsor's request | 3 |
| Withdrew: Other | 6 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE that was attributed to study drug in a participant who received study drug was defined as an adverse reaction. Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.
| participants | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Adverse event (all causalities) | 343 |
| Adverse reaction | 207 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of adverse event was defined on the basis of severity of an event and was classified as; mild (does not interfere with participant's usual function), moderate (interferes to some extent with participant's usual function) and severe (interferes significantly with participant's usual function). Treatment-emergent are events between first dose of study drug and up to end of study (2 weeks post-end of month 12) that were absent before treatment or that worsened relative to pretreatment state.
| participants | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Mild | 94 |
| Moderate | 202 |
| Severe | 47 |
The presence and level of clinical opiate withdrawal signs or symptoms was determined by clinician-administered, clinical opiate withdrawal scale (COWS). It contains 11 common opiate withdrawal signs or symptoms rated by clinician (resting pulse rate, gastrointestinal upset, sweating, tremor, restlessness, yawning, pupil size, anxiety or irritability, bone or joint aches, gooseflesh skin, runny nose or tearing), rated on either 3-point, 4-point or 5-point scale, higher score indicated more symptoms of withdrawal. The total score is the sum of all items, ranging from 0 to 48, higher score indicated severe withdrawal. Participants were categorized as less than mild (score 0-4) mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36). Percentage of participants with mild (score 5-12), moderate (score 13-24), moderately severe (score 25-36) or severe (score greater than 36) were reported.
| percentage of participants | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Mild (score 5-12) | 13.2 |
| Moderate (score 13-24) | 0.0 |
| Moderately severe (score 25-36) | 0.3 |
| Severe (score greater than 36) | 0.0 |
The presence and level of clinical opiate withdrawal signs or symptoms was determined by participant-reported instrument, subjective opiate withdrawal scale (SOWS). It contains 16 symptoms of opiate withdrawal rated by the participant (anxiety, yawning, sweating, tearing, running nose, goose bumps, shaking, hot flashes, cold flashes, bone or muscle aches, restlessness, nauseous, vomiting, muscle twitch, stomach cramps and feel like using now). Each item is rated on a 5-point scale (0= not at all, 1= a little, 2= moderate, 3= quite a bit, 4= extreme). The total score is the sum of all items, ranging from 0 to 64, higher score indicated severe withdrawal.
| units on a scale | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Baseline (n= 395) | 5.4 ± 5.49 |
| Week 1 (n= 362) | 4.6 ± 6.15 |
| Week 4 (n= 307) | 3.6 ± 4.32 |
| Month 2 (n= 252) | 3.6 ± 4.70 |
| Month 3 (n= 221) | 3.3 ± 4.53 |
| Month 4 (n= 210) | 2.9 ± 4.30 |
| Month 5 (n= 198) | 3.2 ± 4.56 |
| Month 6 (n= 190) | 2.5 ± 3.27 |
| Month 7 (n= 185) | 2.4 ± 4.07 |
| Month 8 (n= 180) | 2.5 ± 3.74 |
| Month 9 (n= 174) | 2.4 ± 4.08 |
| Month 10 (n= 167) | 2.2 ± 3.25 |
| Month 11 (n= 162) | 2.3 ± 3.53 |
| Month 12 (n= 154) | 2.4 ± 4.09 |
No measurements were reported for this outcome.
Noroxycodone was a metabolite of Oxycodone.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
6-Beta-naltrexol was a metabolite of naltrexone.
No measurements were reported for this outcome.
Stabilization was considered to have occurred when: total daily dose of oxycodone and naltrexone remained unchanged for greater than or equal to (\>=) 3 consecutive days, daily acetaminophen used remained at 1 gram or less and immediate-release oxycodone was not being used as a rescue medication. Days to stabilization = date of stabilization - date of first dose + 1.
| days | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Time to Stabilization of Study Medication | 11.0 (3 to 133) |
Duration of exposure to study medication during the course of the study was assessed.
| days | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Duration of Exposure to Study Medication | 171.0 (1 to 406) |
| milligram/day | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Baseline-less than (<) Week 1 (n= 378) | 38.6 ± 81.27 |
| Week 1-<4 (n= 344) | 51.7 ± 35.53 |
| Week 4-<Month 2 (n= 292) | 62.8 ± 42.65 |
| Month 2-< 3 (n= 238) | 66.1 ± 40.35 |
| Month 3-<4 (n= 217) | 68.0 ± 40.36 |
| Month 4-< 5 (n= 205) | 68.6 ± 41.49 |
| Month 5-<6 (n= 193) | 71.5 ± 43.58 |
| Month 6-<7 (n= 183) | 73.1 ± 43.22 |
| Month 7- <8 (n= 183) | 76.7 ± 43.76 |
| Month 8-<9 (n= 177) | 77.7 ± 45.67 |
| Month 9-<10 (n= 169) | 76.5 ± 44.58 |
| Month 10- <11 (n= 163) | 77.9 ± 44.45 |
| Month 11- <12 (n= 160) | 76.2 ± 43.14 |
| Month 12- <End of study (n= 82) | 26.9 ± 22.79 |
Participants had acetaminophen up to 2 grams per day during the treatment period of the study as rescue medication.
| participants | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Baseline-<Week 1 (n= 387) | 256 |
| Week 1-<4 (n= 361) | 204 |
| Week 4-<Month 2 (n= 305) | 167 |
| Month 2-<3 (n= 252) | 124 |
| Month 3-<4 (n= 222) | 120 |
| Month 4-<5 (n= 209) | 112 |
| Month 5-<6 (n= 199) | 104 |
| Month 6-<7 (n= 191) | 96 |
| Month 7-<8 (n= 185) | 96 |
| Month8-<9 (n= 179) | 93 |
| Month 9-<10 (n= 172) | 79 |
| Month 10-<11 (n= 167) | 80 |
| Month 11-<12 (n= 163) | 85 |
| Month 12-<End of study (n= 95) | 30 |
Participants with a positive urine drug test for illicit drug substances (marijuana, cocaine, amphetamines, methamphetamines, phencyclidine, and ecstasy), or unexpected drug substances (those other than reported by the participant as therapeutic concomitant medications such as opiates and methadone), or a negative urine test for the expected opioid (oxycodone) was assessed.
| percentage of participants | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Screening (n= 393) | 86.8 |
| Week 4 (n= 302) | 41.7 |
| Month 2 (n= 251) | 43.0 |
| Month 3 (n= 222) | 43.2 |
| Month 4 (n= 211) | 39.3 |
| Month 5 (n= 198) | 41.4 |
| Month 6 (n= 190) | 44.2 |
| Month 7 (n= 184) | 41.8 |
| Month 8 (n= 179) | 44.1 |
| Month 9 (n= 174) | 44.8 |
| Month 10 (n= 167) | 44.3 |
| Month 11 (n= 161) | 50.3 |
| Month 12 or early termination (n= 343) | 57.1 |
The COMM is a 17-item self-report questionnaire to monitor for aberrant medication-related behaviors among chronic pain participants. Participants are asked to indicate the frequency of individual behaviors on a scale from 0 to 4 (0 = never, 1 = seldom, 2 = sometimes, 3 = often, 4= very often). The total COMM score is the sum of the 17 item scores with a range from 0 to 68. Higher score indicated a higher risk for aberrant medication- related behavior. A score of 9 or higher was defined as high risk for aberrant medication- related behavior.
| percentage of participants | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Baseline (n= 395) | 21.3 |
| Week 4 (n= 302) | 8.9 |
| Month 2 (n= 250) | 10.0 |
| Month 3 (n= 217) | 8.3 |
| Month 4 (n= 208) | 6.7 |
| Month 5 (n= 197) | 5.1 |
| Month 6 (n= 189) | 2.6 |
| Month 7 (n= 185) | 3.2 |
| Month 8 (n= 181) | 5.0 |
| Month 9 (n= 174) | 5.7 |
| Month 10 (n= 167) | 4.8 |
| Month 11 (n= 162) | 3.7 |
| Month 12 or early termination (n= 333) | 15.3 |
Immediate-release oxycodone as a single ingredient product was used as a rescue medication only during the first 4 weeks of the treatment period to support the initiation of oxycodone HCl and naltrexone HCl treatment.
No measurements were reported for this outcome.
Participant global assessment of treatment satisfaction was scored on a 5-point categorical scale based on response to the question "Please rate your overall satisfaction with the study drug you received?" where 1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = very satisfied.
| unit on a scale | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Week 1 (n= 361) | 3.3 ± 1.03 |
| Week 4 (n= 304) | 3.8 ± 0.99 |
| Month 2 (n= 251) | 3.9 ± 0.94 |
| Month 3 (n= 220) | 4.1 ± 0.88 |
| Month 4 (n= 209) | 4.1 ± 0.93 |
| Month 5 (n= 197) | 4.2 ± 0.90 |
| Month 6 (n= 190) | 4.2 ± 0.89 |
| Month 7 (n= 185) | 4.2 ± 0.81 |
| Month 8 (n= 181) | 4.2 ± 0.81 |
| Month 9 (n= 174) | 4.2 ± 0.96 |
| Month 10 (n= 167) | 4.3 ± 0.73 |
| Month 11 (n= 162) | 4.3 ± 0.79 |
| Month 12 (n= 154) | 4.2 ± 1.04 |
| End of treatment (n= 372) | 3.6 ± 1.27 |
The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain right now" was reported.
| units on a scale | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Baseline (n= 386) | 5.6 ± 2.17 |
| Change at Week 1 (n= 360) | -0.6 ± 2.16 |
| Change at Week 4 (n= 306) | -1.3 ± 2.29 |
| Change at Month 2 (n= 251) | -1.6 ± 2.36 |
| Change at Month 3 (n= 218) | -1.7 ± 2.34 |
| Change at Month 4 (n= 208) | -1.8 ± 2.29 |
| Change at Month 5 (n= 197) | -1.8 ± 2.29 |
| Change at Month 6 (n= 189) | -1.8 ± 2.38 |
| Change at Month 7 (n= 184) | -1.7 ± 2.40 |
| Change at Month 8 (n= 180) | -1.8 ± 2.48 |
| Change at Month 9 (n= 172) | -1.8 ± 2.39 |
| Change at Month 10 (n= 166) | -1.7 ± 2.41 |
| Change at Month 11 (n= 161) | -1.9 ± 2.31 |
| Change at Month 12 (n= 153) | -1.9 ± 2.44 |
| Change at Month 12/ET (n= 373) | -1.4 ± 2.58 |
The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. Pain on average in the last 24 hours" was reported.
| unit on a scale | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Baseline (n= 384) | 5.9 ± 1.74 |
| Change at Week 1 (n= 357) | -0.6 ± 1.64 |
| Change at Week 4 (n= 303) | -1.2 ± 1.95 |
| Change at Month 2 (n= 250) | -1.5 ± 2.11 |
| Change at Month 3 (n= 219) | -1.7 ± 2.12 |
| Change at Month 4 (n= 206) | -1.7 ± 2.04 |
| Change at Month 5 (n= 196) | -1.7 ± 2.02 |
| Change at Month 6 (n= 189) | -1.7 ± 2.11 |
| Change at Month 7 (n= 184) | -1.7 ± 2.17 |
| Change at Month 8 (n= 180) | -1.9 ± 2.12 |
| Change at Month 9 (n= 173) | -1.8 ± 2.21 |
| Change at Month 10 (n= 166) | -1.7 ± 2.26 |
| Change at Month 11 (n= 161) | -1.8 ± 2.02 |
| Change at Month 12 (n= 153) | -1.9 ± 2.23 |
| Change at Month 12/ET (n= 372) | -1.3 ± 2.32 |
The pain intensity scale consisted of 4 questions (pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on the average in the last 24 hours and pain right now) each scored on an 11-point numerical rating scale, where 0 = no pain and 10 = pain as bad as you can imagine. "Pain at its worst in the last 24 hours" was reported.
| unit on a scale | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Baseline (n= 382) | 7.4 ± 1.63 |
| Change at Week 1 (n= 354) | -0.7 ± 1.96 |
| Change at Week 4 (n= 301) | -1.3 ± 2.24 |
| Change at Month 2 (n= 248) | -1.6 ± 2.39 |
| Change at Month 3 (n= 219) | -1.8 ± 2.32 |
| Change at Month 4 (n= 208) | -1.9 ± 2.12 |
| Change at Month 5 (n= 197) | -1.9 ± 2.41 |
| Change at Month 6 (n= 189) | -2.0 ± 2.30 |
| Change at Month 7 (n= 184) | -2.0 ± 2.43 |
| Change at Month 8 (n= 180) | -2.0 ± 2.31 |
| Change at Month 9 (n= 173) | -2.2 ± 2.48 |
| Change at Month 10 (n= 166) | -2.1 ± 2.50 |
| Change at Month 11 (n= 161) | -2.2 ± 2.41 |
| Change at Month 12 (n= 153) | -2.2 ± 2.44 |
| Change at Month 12/ET (n= 368) | -1.6 ± 2.52 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxycodone Hydrochloride (HCl) and Naltrexone HCl | — | 26/395 (6.6%) | 272/395 (68.9%) |
| Event | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Acute myocardial infarctionCardiac disorders | 2/395 |
| Non-cardiac chest painGeneral disorders | 2/395 |
| PneumoniaInfections and infestations | 2/395 |
| ConvulsionNervous system disorders | 2/395 |
| NephrolithiasisRenal and urinary disorders | 2/395 |
| Hypochromic anaemiaBlood and lymphatic system disorders | 1/395 |
| Cardiac failure congestiveCardiac disorders | 1/395 |
| Abdominal painGastrointestinal disorders | 1/395 |
| Hiatus herniaGastrointestinal disorders | 1/395 |
| Pancreatitis acuteGastrointestinal disorders | 1/395 |
| Event | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| NauseaGastrointestinal disorders | 100/395 |
| ConstipationGastrointestinal disorders | 84/395 |
| VomitingGastrointestinal disorders | 55/395 |
| HeadacheNervous system disorders | 46/395 |
| SomnolenceNervous system disorders | 37/395 |
| DiarrhoeaGastrointestinal disorders | 36/395 |
| FatigueGeneral disorders | 36/395 |
| DizzinessNervous system disorders | 34/395 |
| AnxietyPsychiatric disorders | 30/395 |
| Back painMusculoskeletal and connective tissue disorders | 25/395 |
Safety analysis set included all enrolled participants who had at least 1 dose of oxycodone HCl and naltrexone HCl extended-release capsules.
| Age, Continuous(years) | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Mean | 53.8 ± 12.10 |
| Sex: Female, Male(Participants) | Oxycodone Hydrochloride (HCl) and Naltrexone HCl |
|---|---|
| Female | 203 |
| Male | 192 |
The record gives a start of Dec 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 4 years 6 months after primary completion. A results delay was requested in Jul 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxycodone · Naltrexone